This CME program will analyze recent advances in the treatment and management of patients with of chronic inflammatory demyelinating polyneuropathy (CIDP). The expert faculty, Dr. Jeffrey Allen, will outline the pathophysiology and disease burden of CIDP as well as the role of igG antibodies. Dr. Allen will utilize a case-based approach to highlight a typical journey to CIDP diagnosis, including diagnostic challenges and strategies for distinguishing CIDP variants from mimics. Following, Dr. Allen will provide an in-depth analysis of current clinical trial data on new and emerging biologic treatments for CIDP, touching on unmet needs and the role of shared decision making in improving patient outcomes. Upon completion of this CME program, learners will be better equipped to treat and manage their patients with chronic inflammatory demyelinating polyneuropathy.
Neurologists, APPs working in neurology practices, and other healthcare providers caring for patients with CIDP
Review the pathophysiology and disease burden of CIDP, the role of IgG autoantibodies, accurate patient identification and diagnosis, and the limitations of current treatments
Analyze recent clinical trial data on new and emerging biologic treatments for CIDP and be prepared to contextualize these data into their practices
Develop individualized treatment plans for CIDP based on patient prognosis, a review of treatment options, an assessment of safety, familiarity with current treatment guidelines, and shared decision making
Provide an overview of the prevalence, key diagnostic features and diagnostic challenges of chronic inflammatory demyelinating polyneuropathy (CIDP)
Review our current understanding of the immunobiology of CIDP
Discuss the current treatment landscape of CIDP, and unmet needs when treating patients
Analyze recent clinical trial data on new and emerging biologic treatments for CIDP
Discuss the role of shared decision making when optimizing CIDP patient care
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty
have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Jeffrey Allen, MD
| Consultant/Advisor: Alexion Pharmaceuticals; Alnylam Pharmaceuticals; argenx; AstraZeneca; CSL Behring; Grifols; Immupharma PLC; Nuvig Therapeutics, Inc.; Octapharma; Immunovant, Inc.; Sanofi; Takeda Pharmaceuticals |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin and Chelsey Simonds hereby state that they do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
This activity has been supported by an independent educational grant from argenx.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and argenx do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
811 S. Orleans Ave. Tampa, Fl 33606
